Rinat Neuroscience Corporation Begins Clinical Testing Of Potential First-In-Class Pain Therapeutic
10/19/2005 5:08:49 PM
Rinat Neuroscience, a privately held biotechnology company, today announced the initiation of Phase 1 human safety testing of the company's lead investigational therapeutic, RI 624. The company discovered and is developing RI 624, a humanized monoclonal antibody that inhibits nerve growth factor (NGF), for the treatment of both acute and chronic pain.
comments powered by